Logo image of NNVC

NANOVIRICIDES INC (NNVC) Stock Fundamental Analysis

USA - NYSE Arca - NYSEARCA:NNVC - US6300873022 - Common Stock

1.11 USD
+0.02 (+1.83%)
Last: 12/3/2025, 8:04:00 PM
1.1187 USD
+0.01 (+0.78%)
After Hours: 12/3/2025, 8:04:00 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to NNVC. NNVC was compared to 534 industry peers in the Biotechnology industry. The financial health of NNVC is average, but there are quite some concerns on its profitability. NNVC is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NNVC has reported negative net income.
In the past year NNVC has reported a negative cash flow from operations.
NNVC had negative earnings in each of the past 5 years.
In the past 5 years NNVC always reported negative operating cash flow.
NNVC Yearly Net Income VS EBIT VS OCF VS FCFNNVC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -2M -4M -6M -8M -10M

1.2 Ratios

NNVC has a Return On Assets of -97.23%. This is in the lower half of the industry: NNVC underperforms 73.97% of its industry peers.
NNVC has a Return On Equity (-113.25%) which is in line with its industry peers.
Industry RankSector Rank
ROA -97.23%
ROE -113.25%
ROIC N/A
ROA(3y)-38.17%
ROA(5y)-46.67%
ROE(3y)-40.8%
ROE(5y)-52.73%
ROIC(3y)N/A
ROIC(5y)N/A
NNVC Yearly ROA, ROE, ROICNNVC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NNVC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NNVC Yearly Profit, Operating, Gross MarginsNNVC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, NNVC has more shares outstanding
Compared to 5 years ago, NNVC has more shares outstanding
There is no outstanding debt for NNVC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NNVC Yearly Shares OutstandingNNVC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M
NNVC Yearly Total Debt VS Total AssetsNNVC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

2.2 Solvency

NNVC has an Altman-Z score of -18.33. This is a bad value and indicates that NNVC is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -18.33, NNVC is doing worse than 83.71% of the companies in the same industry.
NNVC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -18.33
ROIC/WACCN/A
WACCN/A
NNVC Yearly LT Debt VS Equity VS FCFNNVC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M 30M

2.3 Liquidity

A Current Ratio of 1.06 indicates that NNVC should not have too much problems paying its short term obligations.
NNVC has a Current ratio of 1.06. This is amonst the worse of the industry: NNVC underperforms 86.70% of its industry peers.
A Quick Ratio of 1.06 indicates that NNVC should not have too much problems paying its short term obligations.
NNVC has a Quick ratio of 1.06. This is amonst the worse of the industry: NNVC underperforms 86.33% of its industry peers.
Industry RankSector Rank
Current Ratio 1.06
Quick Ratio 1.06
NNVC Yearly Current Assets VS Current LiabilitesNNVC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 32.53% over the past year.
EPS 1Y (TTM)32.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.17%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

NNVC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.12% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-12.5%
EPS Next 2Y2.47%
EPS Next 3Y1.64%
EPS Next 5Y8.12%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NNVC Yearly Revenue VS EstimatesNNVC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2029 2030 200M 400M 600M 800M 1B
NNVC Yearly EPS VS EstimatesNNVC Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2021 2022 2023 2024 2025 2026 2027 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NNVC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NNVC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NNVC Price Earnings VS Forward Price EarningsNNVC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NNVC Per share dataNNVC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.47%
EPS Next 3Y1.64%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NNVC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NANOVIRICIDES INC

NYSEARCA:NNVC (12/3/2025, 8:04:00 PM)

After market: 1.1187 +0.01 (+0.78%)

1.11

+0.02 (+1.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2025-11-14/amc
Earnings (Next)02-12 2026-02-12
Inst Owners8.31%
Inst Owner Change7.19%
Ins Owners0.6%
Ins Owner Change0%
Market Cap19.98M
Revenue(TTM)N/A
Net Income(TTM)-8.13M
Analysts82.86
Price Target7.14 (543.24%)
Short Float %1.31%
Short Ratio0.73
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)7.69%
PT rev (3m)7.69%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.78
P/tB 2.91
EV/EBITDA N/A
EPS(TTM)-0.51
EYN/A
EPS(NY)-0.58
Fwd EYN/A
FCF(TTM)-0.42
FCFYN/A
OCF(TTM)-0.42
OCFYN/A
SpS0
BVpS0.4
TBVpS0.38
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -97.23%
ROE -113.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-38.17%
ROA(5y)-46.67%
ROE(3y)-40.8%
ROE(5y)-52.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 13.88%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.06
Quick Ratio 1.06
Altman-Z -18.33
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)32.55%
Cap/Depr(5y)21.81%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.17%
EPS Next Y-12.5%
EPS Next 2Y2.47%
EPS Next 3Y1.64%
EPS Next 5Y8.12%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y14.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-9.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-11.77%
OCF growth 3YN/A
OCF growth 5YN/A

NANOVIRICIDES INC / NNVC FAQ

What is the fundamental rating for NNVC stock?

ChartMill assigns a fundamental rating of 2 / 10 to NNVC.


What is the valuation status of NANOVIRICIDES INC (NNVC) stock?

ChartMill assigns a valuation rating of 0 / 10 to NANOVIRICIDES INC (NNVC). This can be considered as Overvalued.


What is the profitability of NNVC stock?

NANOVIRICIDES INC (NNVC) has a profitability rating of 0 / 10.


How financially healthy is NANOVIRICIDES INC?

The financial health rating of NANOVIRICIDES INC (NNVC) is 5 / 10.